Revolution Medicines: 140% Gain, Still a Buy?

Revolution Medicines (RVMD) has seen its stock price skyrocket nearly 140% in 2026, driven by positive late-stage clinical trial results for its lead candidate, daraxonrasib, in pancreatic cancer. The company specializes in targeting RAS proteins, once considered 'undruggable,' using its tri-complex inhibitor platform.

In a phase 3 trial for previously treated metastatic pancreatic cancer, daraxonrasib achieved a median survival of 13.2 months versus 6.7 months for standard chemotherapy—nearly doubling survival. The company considers these results final and plans to submit them for regulatory review.

Revolution also has a robust pipeline, including zoldonrasib in phase 3 for the same indication, daraxonrasib in phase 3 for non-small cell lung cancer, and earlier-stage trials in colorectal cancer. The company aims to share combination study results later this year.

Despite no approved products or revenue yet, Revolution holds $1.9 billion in cash and raised $2.1 billion in net proceeds from financing to support ongoing R&D. The recent quarter's loss doubled to over $453 million, typical for a clinical-stage biotech investing heavily in development.

Revolution's progress is significant because it addresses a major unmet need in oncology—pancreatic cancer, where treatment options are limited. The survival benefit demonstrated in the phase 3 trial positions daraxonrasib as a potential new standard of care, which could drive substantial revenue if approved.

For investors, the stock's 140% gain reflects growing confidence in the technology platform. However, the company remains pre-revenue, meaning the stock price is based on future expectations rather than current earnings. A regulatory approval would reduce risk and validate the platform across the pipeline.

The company's strong cash position provides a runway through key milestones, including potential FDA submissions and ongoing trials. If daraxonrasib gains approval, it could generate significant sales, and the pipeline's breadth offers additional upside from other indications.

Competitors in the RAS-targeting space include Amgen (AMGN) with sotorasib and Mirati Therapeutics (now part of Bristol Myers Squibb) with adagrasib, but Revolution's tri-complex approach targets a broader range of RAS mutations, potentially giving it a competitive edge.